Free Trial

15 Stocks That Insiders Won't Stop Buying - 7 of 15

 
 

Kiora Pharmaceuticals (NASDAQ:KPRX)

Dollar Amount of Shares Purchased
$64,388.79
Number of Insider Purchases in the Last 180 Days
6
Volume of Shares Purchased
14,041
Who Bought Shares
Aron Shapiro (Director), Brian M Strem (CEO), Eric Joseph Daniels (Insider), Erin Parsons (Director), Lisa Walters-Hoffert (Director) and Melissa Tosca (EVP)

Insider Trades by Quarter for Kiora Pharmaceuticals (NASDAQ:KPRX)

About Kiora Pharmaceuticals

Kiora Pharmaceuticals logoKiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. Read More 
 
 

Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now